Focus Partners Wealth Grows Stock Holdings in Edwards Lifesciences Corporation $EW

Focus Partners Wealth lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.1% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 67,271 shares of the medical research company’s stock after buying an additional 3,891 shares during the quarter. Focus Partners Wealth’s holdings in Edwards Lifesciences were worth $4,876,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC increased its holdings in Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after acquiring an additional 145 shares during the last quarter. Dynamic Advisor Solutions LLC increased its holdings in Edwards Lifesciences by 2.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company’s stock valued at $1,124,000 after acquiring an additional 370 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Edwards Lifesciences by 13.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock valued at $5,582,000 after acquiring an additional 9,188 shares during the last quarter. United Asset Strategies Inc. increased its holdings in Edwards Lifesciences by 10.4% in the 1st quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company’s stock valued at $13,450,000 after acquiring an additional 17,412 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in Edwards Lifesciences by 390.7% in the 1st quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company’s stock valued at $633,000 after acquiring an additional 7,013 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Mizuho boosted their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Citigroup restated a “buy” rating and issued a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Finally, William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $86.26.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $77.50 on Monday. The company has a 50 day moving average price of $78.92 and a 200-day moving average price of $75.45. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The stock has a market capitalization of $45.50 billion, a PE ratio of 11.15, a PEG ratio of 3.74 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the prior year, the company earned $0.70 EPS. The company’s revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.